News | May 04, 2012

New Balloon Catheter System Shows Promise to Advance Endovascular Technique

May 4, 2012 - A new balloon catheter system could advance the endovascular approach to treating obstructed arteries in the leg, offering an alternative to surgical revascularization. Peripheral artery disease affects about 12 to 14 percent of the general population. Revascularization can be achieved through bypass surgery or a number of minimally invasive endovascular techniques that seek to reduce or eliminate symptoms of reduced blood flow by improving tissue perfusion. Chronic total occlusions of the superficial femoral artery and popliteal artery, some of the most difficult lesions to recanalize with conventional guidewire techniques, were treated with this new system.

This first-in-man experience of the Enabler-P Balloon Catheter System is reported in the current issue of the Journal of Endovascular Therapy. The Enabler-P Balloon Catheter System features a unique balloon-anchoring mechanism and an automated balloon inflation device that allows steady, controlled guidewire advancement by the operator through an occlusion. The new system incorporates increased top force and better pushability of a standard guidewire.

Thirty-seven patients with a variety of occlusions, including heavily calcified, long and fibrotic lesions, participated in the study. A successful procedure was achieved in 86 percent. The average time to successfully navigate the occlusion was 5.3 minutes. Physicians participating in the study reported success in maintaining positioning of the guidewire in the lumen of the blood vessel, even in curvilinear and other challenging areas.

The authors of a commentary about this article welcome this test of new endovascular techniques and tools. Although an increasing
number of facilities favor first trying an endovascular approach to obstructed arteries in the leg, there is a lack of adequately designed clinical studies helping to establish these techniques. The authors note that this new system may offer new possibilities and change attitudes toward lower limb revascularization in the setting of critical limb ischemia.

For more information: www.jevtonline.org/toc/enth/19/2

 


Related Content

News | Balloon Catheter

June 13, 2024 — The U.S. Food and Drug Administration (FDA) announced that Teleflex, and their subsidiary Arrow ...

Home June 13, 2024
Home
News | Balloon Catheter

April 4, 2024 — The U.S. Food and Drug Administration (FDA) announced that Medos International Sàrl is recalling ...

Home April 04, 2024
Home
News | Balloon Catheter

January 18, 2024 — Summa Therapeutics, LLC announced that the first-in-man injectable angioplasty procedures for ...

Home January 18, 2024
Home
News | Balloon Catheter
Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional ...
Home February 25, 2022
Home
News | Balloon Catheter

February 15, 2022 – CERENOVUS, an emerging leader in neurovascular care and part of Johnson & Johnson Medical Devices ...

Home February 15, 2022
Home
News | Balloon Catheter

May 20, 2021 — Boston Scientific Corporation announced it has initiated the AGENT IDE trial for the Agent Drug-Coated ...

Home May 20, 2021
Home
Feature | Balloon Catheter | By Dave Fornell, Editor

The first devices developed for interventional cardiology were percutaneous transluminal coronary angioplasty (PTCA) ...

Home March 16, 2021
Home
Feature | Balloon Catheter

February 17, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Shockwave Medical's Intravascular ...

Home February 17, 2021
Home
News | Balloon Catheter

June 4, 2020 — Transit Scientific announced the U.S. Food and Drug Administration (FDA) cleared the XO Score ...

Home June 04, 2020
Home
News | Balloon Catheter

February 24, 2020 — Abbott has voluntarily recalled specific lots of two types of its coronary angioplasty catheters — ...

Home February 24, 2020
Home
Subscribe Now